StockNews.AI
STXS
StockNews.AI
119 days

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

1. Stereotaxis will release Q1 2025 financial results on May 12, 2025. 2. A conference call will discuss results and corporate developments. 3. Stereotaxis is a leader in surgical robotics for minimally invasive procedures. 4. Their technology has treated over 150,000 patients worldwide. 5. The company aims to enhance patient care and operating room efficiency.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results can drive positive momentum. Positive announcements often lead to stock price increases.

How important is it?

The earnings call is crucial for investors looking for growth indicators.

Why Short Term?

Financial results are expected soon, creating immediate interest from investors.

Related Companies

ISRGIRDM
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 4794777.  Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.  Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.   About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Related News